Ibionext
iBionext is France's first Venture Studio dedicated to healthcare, specializing in the creation, development, and financing of innovative startups in biotech, medtech, digital health, and deep tech sectors. Founded in 2012 and based in Paris, it has co-founded and built multiple high-potential companies and raised over €600 million collectively since inception.
Ibionext is a Paris venture capital firm with €600M AUM, 5 active companies and 4 exits.
Sector breakdown
9 companiesKey facts
Recent exits
Ibionext sold Chronolife to TRAAK in 2025 after 8 years.
Ibionext sold GrAI Matter Labs to Snap in 2023 after 7 years.
Ibionext took GenSight Biologics public in 2016 after 4 years.
Ibionext took Pixium Vision public in 2014 after 3 years.
Coverage notes
1 fund tracked, 9 portfolio companies (5 active · 4 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Ibionext has raised, with its portfolio companies. Hand-checked from public filings.
iBionext Growth FundharvestingVC2018€90M5 assets4 exitsVC2018 · 8yr€90M54
Unrealized
5 held| Company | Entry |
|---|---|
| BrainEver Healthcare · France | 2017 |
| Prophesee Deep Tech · France | 2014 |
| T-Heart Healthcare · France | 2018 |
| Tilak Healthcare HealthTech · France | 2016 |
| Tissium MedTech · France | 2013 |
Realized
4 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Chronolife HealthTech · France | 2017 | 2025 | Trade Sale | TRAAK | – |
| GenSight Biologics Biotech · France | 2012 | 2016 | IPO | – | – |
| GrAI Matter Labs TMT · France | 2016 | 2023 | Trade Sale | Snap | – |
| Pixium Vision MedTech · France | 2011 | 2014 | IPO | – | – |
About Ibionext
iBionext is France's first Venture Studio dedicated to healthcare, with €600 million of assets under management as of December 2024, founded in 2015 and headquartered in Paris. The firm specialises in the creation, development and financing of innovative startups in biotech, MedTech, digital health and deep tech sectors, combining venture capital deployment with active company-building expertise.
Investment thesis
iBionext combines venture studio operations (creating new companies internally) with traditional venture capital investments in external biotech, MedTech, digital health and deep tech startups. Investment stages span early-stage seed and Series A with selective growth-stage follow-on commitments. The venture studio model distinguishes iBionext from pure VC peers, enabling proactive company-building alongside selective external investments where market opportunities align with the platform's healthcare focus.
Recent activity
The platform tracks a single dedicated fund vehicle and 6 active portfolio companies across the venture studio and traditional VC programmes. As a venture studio with selective external investments, iBionext maintains long-duration positions aligned with the multi-year company-building cycles typical of healthcare innovation.
Frequently asked questions
- What investment strategy does Ibionext focus on?
- Ibionext focuses on VC, Growth, Buyout strategies in the private equity space.
- How many portfolio companies does Ibionext have?
- Ibionext has 5 active portfolio companies and 4 completed exits and 1 fund tracked on GP Intel.
- Where is Ibionext headquartered?
- Ibionext is headquartered in Paris, France.
- What is Ibionext's assets under management?
- Ibionext manages approximately €600M in assets under management.
- When was Ibionext founded?
- Ibionext was founded in 2015.
- What sectors does Ibionext invest in?
- Ibionext invests across Healthcare, Software, TMT, Industrials.
- What are Ibionext's recent exits?
- Recent realized exits by Ibionext include: Chronolife (2025) to TRAAK; GrAI Matter Labs (2023) to Snap.
Similar firms
Other private equity firms tracked on GP Intel.
France·€600M
France·€600M
France·€600M
France·€600M
France·€600M
France·€604M
France·€625M
France·€635M
France·€650M
France·€550M
France·€550M
France·€650M